Polaryx shareholders re-elect Alex Yang, Mitchel Berger as Class I directors

Polaryx Therapeutics, Inc.

Alex Yang and Mitchel Berger re-elected as Class I directors at Sept 10, 2026 annual meeting.
Each director received 30,072,137 votes for, 332 withheld, with 472,610 broker non-votes.
Ratification of Grant Thorton LLP as auditor for FY2026 approved: 30,510,106 for, 34,973 against.
Directors will serve until the 2029 annual meeting of stockholders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.